Cargando…

Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer

Synthetic biology enables the engineering of bacteria to safely deliver potent payloads to tumors for effective anti-cancer therapies. However, a central challenge for translation is determining ideal bacterial therapy candidates for specific cancers and integrating them with other drug treatment st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deb, Dhruba, Wu, Yangfan, Coker, Courtney, Harimoto, Tetsuhiro, Huang, Ruoqi, Danino, Tal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748036/ https://www.ncbi.nlm.nih.gov/pubmed/36513723 http://dx.doi.org/10.1038/s41598-022-26105-1

Ejemplares similares

A programmable encapsulation system improves delivery of therapeutic bacteria in mice
por: Harimoto, Tetsuhiro, et al.
Publicado: (2022)

Assessing chemotherapy dosing strategies in a spatial cell culture model
por: Deb, Dhruba, et al.
Publicado: (2022)

Programmable bacteria induce durable tumor regression and systemic antitumor immunity
por: Chowdhury, Sreyan, et al.
Publicado: (2019)

Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
por: Savage, Thomas M., et al.
Publicado: (2023)

Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases
por: Barra, Maria, et al.
Publicado: (2020)

Reprogramming the proteome for cell-free protein expression
por: Harimoto, Tetsuhiro
Publicado: (2020)

Engineered Bacteria for Short-Chain-Fatty-Acid-Repressed Expression of Biotherapeutic Molecules
por: Serebrinsky-Duek, Kineret, et al.
Publicado: (2023)

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2020)

Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
por: Paes, Bosco, et al.
Publicado: (2013)

Synchronized cycles of bacterial lysis for in vivo delivery
por: Din, M. Omar, et al.
Publicado: (2016)

Systems and synthetic biology-driven engineering of live bacterial therapeutics
por: Kim, Kangsan, et al.
Publicado: (2023)

Therapeutic vaccines in non-small cell lung cancer
por: Socola, Francisco, et al.
Publicado: (2013)

Hypokalemia with Trifluoperazine at Therapeutic Dose
por: Rehman, Sajjadur, et al.
Publicado: (2017)

Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer
por: Courtney, P. Travis, et al.
Publicado: (2021)

Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer
por: Yu, Renzhi, et al.
Publicado: (2018)

A synchronized quorum of genetic clocks
por: Danino, Tal, et al.
Publicado: (2010)

Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
por: Bramsen, Jesper B., et al.
Publicado: (2012)

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
por: Césaire, Mathieu, et al.
Publicado: (2022)

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer
por: Sirhan, Zaid, et al.
Publicado: (2023)

Engineering protein-based therapeutics through structural and chemical design
por: Ebrahimi, Sasha B., et al.
Publicado: (2023)

Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Xiang, Yi, et al.
Publicado: (2022)

Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
por: Adderley, H., et al.
Publicado: (2020)

Biomaterial therapeutic strategies for treatment of bacterial lung infections
por: Chee, Eunice, et al.
Publicado: (2023)

Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management
por: Rao, Satish S. C., et al.
Publicado: (2019)

Breathing in vitro: Designs and applications of engineered lung models
por: Nossa, Roberta, et al.
Publicado: (2021)

Design, Optimization and Application of Small Molecule Biosensor in Metabolic Engineering
por: Liu, Yang, et al.
Publicado: (2017)

Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports
por: Liu, Ruoqi, et al.
Publicado: (2019)

Actual status of therapeutic vaccination in non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga, Noriaki, et al.
Publicado: (2015)

Emerging therapeutic agents for advanced non-small cell lung cancer
por: Chen, Ruqin, et al.
Publicado: (2020)

Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
por: Zou, Jiayu, et al.
Publicado: (2021)

Therapeutic efficacy of hydrogen-rich saline alone and in combination with PI3K inhibitor in non-small cell lung cancer
por: Jiang, Yu, et al.
Publicado: (2018)

A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer
por: Zhao, Qingda, et al.
Publicado: (2020)

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
por: Morimoto, Kenji, et al.
Publicado: (2021)

Combined small-cell lung carcinoma
por: Qin, Jing, et al.
Publicado: (2018)

In-Silico Patterning of Vascular Mesenchymal Cells in Three Dimensions
por: Danino, Tal, et al.
Publicado: (2011)

In Vivo Gene Expression Dynamics of Tumor-Targeted Bacteria
por: Danino, Tal, et al.
Publicado: (2012)

Developing a new class of engineered live bacterial therapeutics to treat human diseases
por: Charbonneau, Mark R., et al.
Publicado: (2020)

Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering
por: Adolfsen, Kristin J., et al.
Publicado: (2021)

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
por: Flieswasser, Tal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ti1s9sag1vphde149p9vdv303c